Incyte (INCY) President Pablo J Cagnoni Sells $298K of Stock

Pablo J Cagnoni, President and Global Head of R&D at Incyte Corporation, sold 2,642 shares of the company on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the shares were disposed of at an average price of $112.71, totaling roughly $297,779. The stock closed at $113.27 on the day of the transaction.

INCY Incyte Corporation

$113.07 ▲ +11.49% year to date

1M 3M YTD

Daily close · Oct 16, 2026

Inside Pablo J Cagnoni's INCY Trade

The sale took place under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Cagnoni directly held 183,200 shares of Incyte, marking a roughly 1.4% decrease in direct holdings.

Other Institutional Activity in Incyte Corporation

Baker Bros. Advisors, LP grew its holdings by 18,446 shares, ending with 30,762,330 shares worth about $3.48 billion. Dodge & Cox Inc. reduced its holdings by 295,288 shares, ending with 11,957,326 shares worth about $1.35 billion. AQR Capital Management, LLC cut its stake by 487,309 shares, ending with 5,320,901 shares valued at about $602.59 million. Dodge & Cox trimmed its position by 1,009,386 shares, leaving it with 12,252,356 shares worth roughly $1.31 billion. Avoro Capital Advisors sold out its position entirely, liquidating 135,000 shares.

Incyte Corporation Stock Down 9.6%

The stock recently traded around $113.25 as of October 19, 2026, sitting close to its close of $113.27 on the trade date.

Recent Earnings

Incyte posted trailing twelve-month revenue of $5.82 billion with a year-over-year revenue growth rate of 37.7%. The biopharmaceutical firm reported trailing earnings of $7.84 per share, alongside a net profit margin of 27.7% and a return on equity of 30.7%. The company's next earnings report is slated for October 27, 2026.

Dividend

The company maintains a dividend payout ratio of 0.0%.

Insider Buying and Selling at Incyte Corporation

Earlier insider transactions at Incyte featured multiple sales by executives. Pablo J Cagnoni sold 23,218 shares on September 15, 2026. Cagnoni also sold 10,801 shares at $125.56 on August 19, 2026, and 10,803 shares at $120.04 on August 12, 2026. Officer Patrick A Mayes sold 2,207 shares at $123.99 on August 5, 2026.

Analysts Set New Price Targets

Truist Securities maintained a Hold rating on Incyte with a price target of $115 on October 14, 2026. HC Wainwright & Co. reiterated a Buy rating with a target of $152 on October 13, 2026. RBC Capital maintained a Sector Perform rating with a target of $114 on October 8, 2026. Stifel kept a Buy rating with a target of $157 on October 5, 2026, while Wells Fargo maintained an Equal-Weight rating and raised its target to $128 on October 1, 2026.

About Incyte Corporation

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that discovers, develops, and commercializes targeted therapeutics for patients in major global markets. The firm focuses on advancing medicines in fields like oncology and inflammation.

Bottom Line

Investors tracking Incyte will look toward the upcoming October 27 earnings release for fresh operational updates. Form 4 filings will continue to provide visibility into executive equity adjustments.